Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026

NSE: SUNPHARMA · 13 October 2026 · Pre-market update

Previous close
₹1,760.00
Previous day change
+0.01%
High / Low
₹1,776.80 / ₹1,751.00
Volume
13.46 lakh
Previous trading day
9 October 2026
Key Takeaways
  • Sun Pharmaceutical Industries Limited is in focus ahead of the market open following its board meeting outcome on October 12, 2026. The company announced the approval of raising up to INR 10,000 Crore via Non-Convertible Debentures and noted the resignation of Non-Executive Independent Director Mr. Gautam Doshi.
  • The board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for an aggregate amount not exceeding INR 10,000 Crore. The finance committee has been authorized to determine tranche-specific terms.
  • Trading volume was 0.83 times the 20-day average daily volume.

Sun Pharmaceutical Ind L Company News Before Market Open

Sun Pharmaceutical Industries Limited is in focus ahead of the market open following its board meeting outcome on October 12, 2026. The company announced the approval of raising up to INR 10,000 Crore via Non-Convertible Debentures and noted the resignation of Non-Executive Independent Director Mr. Gautam Doshi.

The board-approved INR 10,000 Crore non-convertible debentures issuance sets up significant debt-capital fundraising activity. The departure of independent director Gautam Doshi alters board committee structures. Prior session context shows the stock closed at 1760.0 on October 9, 2026, amid broader 20-day downward price pressure.

13.46 lakh shares traded on 9 October 2026. This compares with a 20-day average daily volume of 16.15 lakh shares (0.83 times). The five-day average daily volume was 15.68 lakh shares.

Company-specific context
Board Approves Non-Convertible Debentures Issuance up to INR 10,000 Crore and Notes Director Resignation

The board-approved INR 10,000 Crore non-convertible debentures issuance sets up significant debt-capital fundraising activity. The departure of independent director Gautam Doshi alters board committee structures. Prior session context shows the stock closed at 1760.0 on October 9, 2026, amid broader 20-day downward price pressure.

Latest Company Developments

Sun Pharma Board Approves NCD Issuance up to INR 10,000 Crore
12 October 2026

The board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for an aggregate amount not exceeding INR 10,000 Crore. The finance committee has been authorized to determine tranche-specific terms.

The capital raise plans indicate strategic funding maneuvers that will be closely analyzed by market participants.

Non-Executive Independent Director Gautam Doshi Resigns
12 October 2026

Mr. Gautam Doshi has resigned from his position as a Non-Executive, Independent Director of the company effective October 12, 2026, citing personal commitments and confirming no other material reasons.

Board composition changes in key independent oversight roles attract governance-related focus from investors.

Outcome of Board Meeting
13 October 2026

Outcome of the Board Meeting held on 12 October 2026

Original source →

Ownership & Transaction Activity

Shareholding
As of 30 June 2026
Promoter holding
54.48%
54.48% on 31 March 2026
FII/FPI
14.53%
15.93% on 31 March 2026
Institutional holding
36.71%
37.04% on 31 March 2026

NSE shareholding filing →

Mutual Fund Holdings

Mutual-fund ownership

Mutual funds held 12.84% on 30 June 2026. This compares with 11.96% on 31 March 2026, a change of +0.88 percentage points.

The filing reported 49 MF/UTI holders.

Icici Prudential Value Fund
30 June 2026
8.92 crore shares · 3.72%
Sbi Nifty 50 Etf
30 June 2026
5.67 crore shares · 2.36%
Nippon Life India Trustee Ltd-A/C Nippon India Large Cap Fund
30 June 2026
3.31 crore shares · 1.38%
These are quarterly holdings, rather than purchases or sales on the article date.

NSE shareholding filing →

Historical Bulk / Block Deals

The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794
24 June 2026
Buy · 1.54 lakh shares · ₹1,868.00

Public market-data page
The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828
24 June 2026
Sell · 1.54 lakh shares · ₹1,868.00

Public market-data page

What to Watch Next

  • Trading volumes and institutional participation following the debt-raising announcement.
  • Further disclosures regarding the tranche-specific terms and timelines of the NCD issuances.
  • Price action relative to the 20-day average close of 1829.09 and support levels near the prior session low of 1751.0.

Other Dated Coverage

More Sun Pharmaceutical Ind L news and dated analysis →

Frequently Asked Questions

What is the latest Sun Pharmaceutical Ind L company news?

The board of directors approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis in one or more tranches for an aggregate amount not exceeding INR 10,000 Crore. The finance committee has been authorized to determine tranche-specific terms.

How strong was Sun Pharmaceutical Ind L’s trading volume?

13.46 lakh shares traded, 0.83 times the 20-day average daily volume. The price and volume data are dated 9 October 2026.

Do the mutual-fund figures show buying today?

They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.

Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst

Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top